Name: Capital Market Publishers India Pvt. Ltd.
Telephone: 91-22-25229720

LOGIN HERE

Cancel

BSE Code : 532612 | NSE Symbol : INDOCO | ISIN : INE873D01024 | Industry : Pharmaceuticals - Indian - Bulk Drugs & Formln |

Board Meeting

Announcement Date	Date Of Meeting	Purpose	Detail
13-Jan-2025	21-Jan-2025	Quarterly Results	INDOCO REMEDIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 21/01/2025 inter alia to consider and approve Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and nine months ended 31-12-2024 Pursuant to the Regulation 30 read with Schedule III and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, we hereby inform you that the Board of Directors of the Company at its Meeting held today i.e. 21st January, 2025 has inter-alia considered and approved the Unaudited Standalone and Consolidated Financial Results for the quarter and nine months ended 31st December, 2024 along with the Limited Review Report with unmodified opinion on the aforesaid Unaudited Financial Results. Unaudited Standalone and Consolidated Financial Results for the quarter and nine months ended 31st December, 2024 (As per BSE Announcement Dated on 21/01/2025)
14-Oct-2024	24-Oct-2024	Quarterly Results	INDOCO REMEDIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 24/10/2024 inter alia to consider and approve The Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half year ended 30-09-2024 Pursuant to the Regulation 30 read with Schedule III and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, we hereby inform you that the Board of Directors of the Company at its Meeting held today i.e. 24th October, 2024 has inter-alia considered and approved the Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended 30th September, 2024 along with the Limited Review Report with unmodified opinion on the aforesaid Unaudited Financial Results. Read less.. Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended 30th September, 2024 (As Per BSE Announcement Dated on 24.10.2024)
10-Jul-2024	23-Jul-2024	Quarterly Results	INDOCO REMEDIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/07/2024 inter alia to consider and approve the Unaudited Standalone & Consolidated Financial Results of the Company for the quarter ended 30-06-2024 Pursuant to the Regulation 30 read with Schedule III and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, we hereby inform you that the Board of Directors of the Company at its Meeting held today i.e. 23rd July, 2024 has inter-alia considered and approved the Unaudited Standalone and Consolidated Financial Results for the quarter ended 30th June, 2024 along with the Limited Review Report with unmodified opinion on the aforesaid Unaudited Financial Results. (As per BSE Announcement Dated on 23/07/2024)
08-May-2024	16-May-2024	Accounts	INDOCO REMEDIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 16/05/2024 inter alia to consider and approve 1. The Audited Standalone and Consolidated Financial Results of the Company for the quarter and year ended 31st March 2024. 2. To recommend a final dividend if any for the financial year ending 31st March 2024. Pursuant to the Regulation 30 read with Schedule III and 33 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015 ('Listing Regulations'), we hereby inform you that the Board of Directors of the Company at its Meeting held today i.e. 16th May, 2024 has inter-alia considered and approved the following. 1. Audited Financial Results (Consolidated and Standalone) for the quarter and year ended 31st March, 2024 and Auditors' Reports with unmodified opinions on the aforesaid Audited Financial Results. 2. Subject to the approval of the Members at the ensuing 77th Annual General Meeting, recommended a Dividend of Rs. 1.50 per equity share on face value of Rs. 2/- for the financial year 2023-2024 Approval of Standalone and Consolidated Financial Results for the Quarter and Year ended 31st March, 2024 (As per BSE Announcement Dated on 16/05/2024)
29-Mar-2024	29-Mar-2024	Change in Auditors	The Board of Directors in its meeting held today i.e. 29th March, 2024 has interalia considered and approved the re-appointment of following auditors for the financial year 2024-2025. 1. M/s A.Y.Sathe & Co., Practicing Company Secretaries as Secretarial Auditor. 2. M/s. B. K. Khare & Co. Chartered Accountants as Internal Auditor. 3. M/s Joshi Apte and Associates, Cost Accountants as Cost Auditor
10-Jan-2024	23-Jan-2024	Quarterly Results	INDOCO REMEDIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/01/2024 inter alia to consider and approve Pursuant to Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 a meeting of the Board of Directors of the Company is scheduled to be held on Tuesday 23rd January 2024 inter alia to consider and approve the unaudited standalone and consolidated financial results of the Company for the quarter and nine months ended 31st December 2023. we hereby inform you that the Board of Directors of the Company at its Meeting held today i.e. 23rd January, 2024 has inter-alia considered and approved the following. 1. Unaudited Standalone and Consolidated Financial Results for the quarter and nine months ended 31st December, 2023 along with the Limited Review Report with unmodified opinion on the aforesaid Unaudited Financial Results. 2. Appointment of Mr. Ajay Mulgaokar (DIN: 10457626) as an Additional Director and Non-Executive Independent Director on the Board of the Company to hold office for a term of five (5) years from 01st April, 2024 to 31st March, 2029, subject to approval of the shareholders. 3. Appointment of Mr. Satish Shenoy (DIN: 00230711) as an Additional Director and Non-Executive Independent Director on the Board of the Company to hold office for a term of five (5) years from 01st April, 2024 to 31st March, 2029, subject to approval of the shareholders. Approval of Unaudited Financial Results for the Quarter and Nine months ended 31st December, 2023 Appointment of Mr. Ajay Mulgaonkar and Mr. Satish Shenoy as a Additional Independent Director of the Company for a term of 5 years w.e.f. 01st April, 2024 to 31st March, 2029 subject to the approval of shareholders (As Per BSE Announcement Dated on 23/01/2024) Newspaper publication of Unaudited Standalone & Consolidated Financial Results for the quarter and nine months ended 31-12-2023 (As Per BSE Announcement Dated on 24/01/2024)
06-Oct-2023	19-Oct-2023	Quarterly Results	INDOCO REMEDIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 19/10/2023 inter alia to consider and approve the unaudited standalone and consolidated financial results of the Company for the quarter and half year ended 30th September 2023. Pursuant to the Regulation 30 read with Schedule III and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, we hereby inform you that the Board of Directors of the Company at its Meeting held today i.e. 19th October, 2023 has inter-alia considered and approved the following. 1. Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended 30th September, 2023 along with the Limited Review Report with unmodified opinion on the aforesaid Unaudited Financial Results. 2. Issuance of a Corporate Guarantee of Rs. 17,00,00,000 in favour of Citibank N.A. in respect of the working capital facilities to be availed by Florida Pharmaceutical Products LLC, step down subsidiary of the Company. Approval of Unaudited Standalone and Consolidated Financial Results for the Quarter and Half year ended 30th September, 2023 The Board of Directors at its meeting held on 19th October, 2023 has interalia considered and approved issuance of a Corporate Guarantee of Rs. 17,00,00,000 in favour of Citibank N.A. in respect of working capital facilities availed by Florida Pharmaceutical Products LLC, step down subsidiary of the Company. (As Per BSE Announcement Dated on 19/10/2023) NEWSPAPER PUBLICATION OF UNAUDITED STANDALONE & CONSOLIDATED FINANCIAL RESULTS FOR THE QTR AND HALF YEAR ENDED 30-09-2023 (As Per BSE Announcement Dated on 20/10/2023)
14-Jul-2023	25-Jul-2023	Quarterly Results	INDOCO REMEDIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/07/2023 inter alia to consider and approve the unaudited standalone and consolidated financial results of the Company for the quarter ended 30th June 2023. Pursuant to the Regulation 30 read with Schedule III and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, we hereby inform you that the Board of Directors of the Company at its Meeting held today i.e. 25th July, 2023 has inter-alia considered and approved the Unaudited Standalone and Consolidated Financial Results for the quarter ended 30th June, 2023 along with the Limited Review Report with unmodified opinion on the aforesaid Unaudited Financial Results. Pursuant to Regulation 33 of SEBI (LODR) Regulations, 2015, we attach herewith the Unaudited Standalone and Consolidated Financial Results for the Quarter ended 30th June, 2023 (As Per BSE Announcement Dated on 25.07.2023)
06-Jun-2023	05-Jun-2023	Acquisitions	In compliance with the provisions of Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the Board of the Directors of the Company at their meeting held on June 5, 2023, approved the acquisition of 85% equity stake in FPP Holding Company, LLC ('FPP Holding'), a company registered in Delaware, USA ('Acquisition'). Consequently, Indoco Remedies Limited ('Company') has executed Equity Purchase Agreement on June 5, 2023 for the Acquisition. Please find enclosed a press release in this regard and details as required under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFO/CMD/4/2015 dated September 9, 2015 in Annexure 'A' and 'B'.
12-May-2023	23-May-2023	Accounts	INDOCO REMEDIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/05/2023 inter alia to consider and approve 1. To consider and approve the Audited Standalone and Consolidated Financial Results of the Company for the quarter and year ended 31st March 2023. 2. To Recommend a final dividend if any for the financial year ending 31st March 2023. Pursuant to the Regulation 30 read with Schedule III and 33 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015 ('Listing Regulations'), we hereby inform you that the Board of Directors of the Company at its Meeting held today i.e. 23rd May, 2023 has inter-alia considered and approved the following. 1. Audited Financial Results (Consolidated and Standalone) for the quarter and year ended 31st March, 2023 and Auditors' Reports with unmodified opinions on the aforesaid Audited Financial Results. 2. Subject to the approval of the Members at the ensuing 76th Annual General Meeting, recommended a Dividend of Rs. 2.25 per equity share on face value of Rs. 2/- for the financial year 2022-2023. Pursuant to the Regulation 30 read with Schedule III and 33 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015 ('Listing Regulations'), we hereby inform you that the Board of Directors of the Company at its Meeting held today i.e. 23rd May, 2023 has considered and approved the Audited Financial Results (Consolidated and Standalone) for the quarter and year ended 31st March, 2023 and Auditors' Reports with unmodified opinions on the aforesaid Audited Financial Results. As per the provisions of Regulation 30 and Part-A of Schedule III of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the Board of the Directors of the Company at their meeting held today i.e. 23rd May, 2023 took note of completion of term of Mr. Suresh G Kare (DIN 00179220) as Chairman and Wholetime Director w.e.f. 30th June, 2023 and re-appointed Mr. Suresh G. Kare as Chairman of the Company in the capacity of Non-Executive Non Independent Director with effect from 01st July, 2023, subject to the approval of shareholders. (As per BSE Announcement Dated on 23/05/2023)
29-Mar-2023	29-Mar-2023	Change in Auditors	1. Re-appointment of M/s A. Y. Sathe & Co, Practicing Company Secretaries, (FCS 2899, COP: 738) as Secretarial Auditor of the Company for the financial year 2023-24. 2. Re-appointment of M/s B. K. Khare & Co., Chartered Accountants having firm Registration No. 105102W as Internal Auditors of the Company for the financial year 2023-24. 3. Re-Appointment of M/s Joshi Apte and Associates, Cost Accountants, having firm Registration No. 00240 as the Cost Auditors of the Company for the financial year 2023-24.
11-Jan-2023	24-Jan-2023	Quarterly Results	INDOCO REMEDIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 24/01/2023 inter alia to consider and approve The standalone and consolidated unaudited financial results of the Company for the quarter and nine months ended 31st December 2022. Pursuant to the Regulation 30 read with Schedule III and 33 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015 ('Listing Regulations'), we hereby inform you that the Board of Directors of the Company at its Meeting held today i.e. 24% January, 2023 has inter-alia considered and approved the Unaudited Standalone and Consolidated Financial Results for the quarter and nine months ended 31st December, 2022 along with the Limited Review Report issued by the Statutory Auditor of the Company. (As Per BSE Announcement Dated on 24/01/2023)
20-Oct-2022	10-Nov-2022	Quarterly Results	INDOCO REMEDIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/11/2022 inter alia to consider and approve Intimation of Board Meeting - Unaudited Financial Results for the quarter & half year ended September 30 2022 The Board of Directors at their meeting held today, have approved and taken on record the Standalone & Consolidated Unaudited financial results of the Company for the second quarter/half year ended 30.09.2022. Enclosed please find copies of the following: a) Standalone & Consolidated unaudited results as per Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 b) Limited Review Certificate issued by our Statutory Auditors M/s. Gokhale & Sathe, Chartered Accountants. c) Press Release. The meeting commenced at 10.45 am and concluded at 11.30 am. The Board of Directors at their meeting held today, have approved and taken on record the Standalone & Consolidated Unaudited financial results of the Company for the second quarter/half year ended 30.09.2022. Enclosed please find copies of the following: a) Standalone & Consolidated unaudited results as per Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 b) Limited Review Certificate issued by our Statutory Auditors M/s. Gokhale & Sathe, Chartered Accountants. c) Press Release. In compliance with the provisions of Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Board of Directors of the Company at their meeting held today i.e. 10th November, 2022 has inter-alia, considered and approved the following:- Mr. Jayshankar Menon (ICSI Membership No.11067) will retire as the Company Secretary and Compliance Officer of the Company with effect from the closure of business hours of 30th November, 2022. In compliance with the provisions of Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Board of Directors of the Company at their meeting held today i.e. 10th November, 2022 has inter-alia, considered and approved the following:- Based on the recommendation of the Nomination and Remuneration Committee and pursuant to Section 203 of the Companies Act, 2013 and Regulation 6(1) of the SEBI LODR Regulations, Mr. Ramanathan Hariharan (ICSI Membership No. A20593) is appointed as the Company Secretary and Compliance Officer of the Company w.e.f. 01st December, 2022 Change in name of Key Managerial Personnel under Regulation 30(5) of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 (As per BSE Announcement Dated on 10/11/2022)
15-Jul-2022	09-Aug-2022	Quarterly Results	INDOCO REMEDIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/08/2022 inter alia to consider and approve Unaudited standalone & consolidated financial results for the quarter ended 30/06/2022 The Board of Directors at their meeting held today, have approved and taken on record the Standalone & Consolidated Unaudited financial results of the Company for the Quarter ended 30th June, 2022. Results for the Quarter ended 30th June 2022 (As Per BSE Announcement Dated on 09.08.2022)
22-Apr-2022	17-May-2022	Quarterly Results	INDOCO REMEDIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 17/05/2022 inter alia to consider and approve a) take on record the audited financial results of the Company for the quarter and year ended 31st March 2022. b) Recommendation of Dividend if any for the financial year 2021-2022 We wish to inform that the Board of Directors of the Company at its meeting held today i.e. 17-05-2022 has interalia considered and approved the following: 1. Audited Financial Results (Standalone and Consolidated) for the Quarter and Financial year ended 31st March, 2022 along with Statutory Auditors Report. 2. Subject to the approval of the Members at the ensuing 75th AGM, recommended a Dividend of Rs.2.25 per share (including a Special Dividend of Rs. 0.75) on face value of Rs. 2/- for the Financial year 2021-2022. 3. Subject to the approval of the Members at the ensuing 75th AGM, recommended the re-appointment of M/s Gokhale & Sathe, Chartered Accountants (Firm Registration No. 103264W) as the Statutory Auditors of the Company for the second term of five years commencing from Financial Year 2022-23. 4. Subject to the approval of the Members at the ensuing 75th AGM, approved the Employee Stock Option Scheme. Pursuant to Regulation 33 of Listing Regulations, we enclose herewith the following: 1. Audited Standalone Financial Results of the Company, as per the IND AS for the quarter and year ended 31st March, 2022 along with Auditors' Report thereon; 2. Audited Consolidated Financial Results of the Company, as per the IND AS for the year ended 31st March, 2022 and auditors report thereon; 3. Copy of Press Release. Pursuant to Regulation 30(2) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform that the Board of the Directors of the Company at its Meeting held today i.e. 17th May, 2022, has recommended the re-appointment of M/s. Gokhale & Sathe, Chartered Accountants, (Firm Registration No. 103264W) as the Statutory Auditors of the Company for the second term of Five Years commencing from the conclusion of the ensuing 75th Annual General Meeting (AGM) of the Company till conclusion of the 80th AGM of the Company to be held in the year 2027, subject to the approval of Shareholders at the Annual General Meeting. (As Per BSE Announcement Dated on 17.05.2022)

1 2

LOGIN HERE

Indoco Remedies Ltd

Board Meeting